Abstract
It already exists within the US Food and Drug Administration, argues a former clinical reviewer of psychotropic drugs at the FDA
Keywords
Related Publications
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the ...
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first t...
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Importance The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. Objective To estimate the rese...
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
The number of published systematic reviews of studies of healthcare interventions has increased rapidly and these are used extensively for clinical and policy decisions. Systema...
Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?
When Archie Cochrane reproached the medical profession for not having critical summaries of all randomised controlled trials, about 14 reports of trials were being published per...
Publication Info
- Year
- 2004
- Type
- editorial
- Volume
- 1
- Issue
- 3
- Pages
- e60-e60
- Citations
- 55
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1371/journal.pmed.0010060